Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.63%
#4 aPriori aPriori +192.70%
#5 Bedrock Bedrock +77.76%
#6 Cysic Cysic +52.73%
#7 Prom Prom +46.24%
#8 Playnance Playnance +34.82%
#9 Bitway Bitway +27.08%
#10 COTI COTI +24.13%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Claritas Pharmaceuticals, Inc. Claritas Pharmaceuticals, Inc.

Claritas Pharmaceuticals, Inc.

CLAZF
Rank in Stocks #42176
Operating as a clinical-stage specialty pharmaceutical entity, Claritas... Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled. Established in 2014, the company was previously known as Kalytera Therapeutics, Inc. before rebranding to Claritas Pharmaceuticals, Inc. in April 2021. Its corporate headquarters are located in San Rafael, California.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$3.66K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Claritas Pharmaceuticals, Inc. (CLAZF)

Category

Healthcare
Revenue for Claritas Pharmaceuticals, Inc. (CLAZF)
Revenue in Aug 2026 TTM: 0
According to Claritas Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Claritas Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR